Nivalin (Galantamine Hydrobromide)

Galantamine reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. By slowing this breakdown, it increases acetylcholine levels at synapses, strengthening cholinergic signaling that is essential for learning and memory. It also modulates nicotinic receptors, adding to its cognitive benefits.

The dosage of Nivalin is determined individually by the prescribing healthcare professional based on the patient’s condition, response, and tolerability. No fixed regimen is provided here; the prescriber will set the appropriate dose and titration schedule.

Safety data for galantamine in pregnancy and lactation are limited. It is generally classified as not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient.

To request Nivalin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative to galantamine is donepezil, another acetylcholinesterase inhibitor. Both improve cognition in Alzheimer’s disease, but galantamine also modulates nicotinic receptors, which may offer additional benefits in attention. Side‑effect profiles differ slightly; galantamine tends to cause more gastrointestinal upset, while donepezil is often associated with insomnia.

Nivalin should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

Nivalin is supplied as a sterile injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection. The route and rate of administration are decided by the treating physician, who will follow aseptic technique and appropriate dosing guidelines.

The most serious adverse events include severe bradycardia or heart block, liver toxicity manifested by elevated enzymes or hepatitis, and rare seizures. Patients should be monitored for signs of these conditions, and treatment should be discontinued if they occur.

Nivalin is contraindicated in patients with known hypersensitivity to galantamine or any formulation components, those with severe cardiac conduction disorders (e.g., sick‑sinus syndrome without a pacemaker), and individuals with uncontrolled asthma or active peptic ulcer disease. Caution is also advised for patients with renal or hepatic impairment.